Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, 2D/3D human lung cell cultures, and efficacy

Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, 2D/3D human lung cell cultures, and efficacy

Inhalable nanostructured microparticles of simvastatin, a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor, were rationally designed for targeted pulmonary delivery as dry powder inhalers (DPIs) for the treatment of pulmonary hypertension (PH). Advanced particle engineering design technology was...

Full description

Bibliographic Details
Main Authors: Maria F. Acosta, Priya Muralidharan, Carissa L. Grijalva, Michael D. Abrahamson, Don Hayes, Jeffrey R. Fineman, Stephen M. Black, Heidi M. Mansour
Format: Article
Language:English
Published: SAGE Publishing 2021-03-01
Series:Therapeutic Advances in Respiratory Disease
Online Access:https://doi.org/10.1177/1753466621998245

Internet

https://doi.org/10.1177/1753466621998245

Similar Items